Results 231 to 240 of about 80,637 (252)

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Journal of Thoracic Oncology, 2020
INTRODUCTION: Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of the multicenter, open-label, phase 1/2 trial of nivolumab ...
Víctor Moreno, Matthew Hellmann, Scott Antonia   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Annals of Oncology, 2021
Hye Ryun Kim, J -H Kang, C-T Yang
exaly  

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary

Annals of Oncology, 2022
Shin Takahashi, Y Takiguchi, J Tanizaki   +2 more
exaly  

The impact of body composition parameters on severe toxicity of nivolumab

European Journal of Cancer, 2020
Jérôme Alexandre, Marie Wislez, Laure Hirsch   +2 more
exaly  

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer Cell, 2018
Joseph D Szustakowski, Naiyer A Rizvi, Matthew Hellmann   +2 more
exaly  

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cell, 2017
Jonathan Schneck, Thomas Gajewski, Rajarsi Mandal   +2 more
exaly  

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Journal of Thoracic Oncology, 2019
Víctor Moreno, Anna Farago, Matthew Hellmann   +2 more
exaly  

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types

Annals of Oncology, 2020
exaly